Houston-based Grab makes it so you're waiting in one less line at the airport. Getty Images

When you fly, you can definitely rely on the fact that you're going to encounter two things: long airport walks and even longer airport lines. This Houston startup is ensuring that you have less of both of those.

Grab is a mobile software company that's designed an app where travelers can see what eateries they are going to pass in their airport visit and order their meal from their phone. The company has also expanded on their technology to include restaurant kiosks and mobile ordering from the table.

Grab was founded by Mark Bergsrud, who worked in senior leadership roles for almost 20 years at Continental Airlines and then United Airlines, following the merger. For Bergsrud, Grab feels like another major mobile game changer the industry experienced.

"I spent many years thinking about the travel experience and how to make it better and faster," Bergsrud says. "This feels like how mobile check in felt. There was a problem customers didn't know they had — check in wasn't that difficult anyway, but to be able to have that control, people love it."

Grab launched in the Atlanta airport in 2015 and now has a presence in 37 airports around the world, including Dallas and Austin though, ironically, not yet either of Houston's airports. Expansion is in the works, says Bergsrud.

"Our strategy is to build a ubiquitous network of partners, marketplace, and restaurants at all major airports," he says.

Also included in Grab's growth plans is to white label the software to include it in existing travel apps, like airline apps. Grab is already integrated into the American Airlines app.

"We don't want customers to have to work hard to figure out they can take advantage of this," Bergsrud says.

Grab, which has grown to a team of 20 people based in Headquarters in EaDo, has new resources to continue its growth. London-based Collinson Group was the sole contributor to Grab's multimillion-dollar Series A round, which closed last week. Along with financial support, the company, which is best known for its Priority Pass lounge membership program, also offers a huge network of partners and years of travel experience.

"We've called ourselves a startup for a long time, and now we think of ourselves as more of a scale-up company," Bergsrud says. "Now it's about having the money to scale faster."

As for where Grab will be scaling, Bergsrud says they are focused on the top 30 airports based on enplanements — including Hobby Airport and George Bush Intercontinental Airport — as well as creating more partnerships with airlines.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.